BIOMERICA, INC. (NASDAQ:BMRA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 21, 2019, Francis Capitanio, age 74, informed Biomerica, Inc. (the “Company”), in writing, of his intention to retire, effective as of April 5, 2019, from all positions held with the Company, including his position as President of the Company.
Mr. Capitanio’s retirement was not as a result of any disagreements with the Company, including on any matters related to its operations, policies or practices. Mr. Capitanio will continue to consult with the Company on an as needed basis.
About BIOMERICA, INC. (NASDAQ:BMRA)
Biomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company’s diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company’s diagnostic products use immunoassay technology.